In Conversation With: Manfred Ruediger, CEO of Ariceum

Theranostic radiopharmaceuticals

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.   

In this episode, Megan Thomas is in conversation with Manfred Ruediger, CEO of Ariceum Therapeutics. Ariceum Therapeutics is focused on developing novel targeted radiopharmaceuticals for the treatment of cancer. 2023 was a pivotal year for the company from a strategic perspective, including a €22.75 million Series A extension in April 2023, a strategic research collaboration with UCB in May 2023, and the acquisition of Theragnostics in June 2023. It was also named Winner of Deal of the Year <500 million EUR at this year’s LSX Leaders European Lifestars Awards 2023. From a pipeline development perspective, 2023 saw the company granted US and Canadian patents for is radiopharmaceutical production kit, as well as promising clinical responses in patients. Ruediger talks about the future for the company and its therapeutic pipeline.

You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts. 

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free